602 related articles for article (PubMed ID: 10674777)
1. Atypical antipsychotic agents: a critical review.
Worrel JA; Marken PA; Beckman SE; Ruehter VL
Am J Health Syst Pharm; 2000 Feb; 57(3):238-55. PubMed ID: 10674777
[TBL] [Abstract][Full Text] [Related]
2. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine: an updated review of its use in the management of schizophrenia.
Bhana N; Foster RH; Olney R; Plosker GL
Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
[TBL] [Abstract][Full Text] [Related]
4. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs.
Ichikawa J; Meltzer HY
Eur Arch Psychiatry Clin Neurosci; 1999; 249 Suppl 4():90-8. PubMed ID: 10654114
[TBL] [Abstract][Full Text] [Related]
5. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
[TBL] [Abstract][Full Text] [Related]
6. Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy.
Markowitz JS; Brown CS; Moore TR
Ann Pharmacother; 1999 Jan; 33(1):73-85. PubMed ID: 9972387
[TBL] [Abstract][Full Text] [Related]
7. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
Kapur S; Zipursky RB; Remington G
Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
[TBL] [Abstract][Full Text] [Related]
8. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.
Toren P; Ratner S; Laor N; Weizman A
Drug Saf; 2004; 27(14):1135-56. PubMed ID: 15554747
[TBL] [Abstract][Full Text] [Related]
9. Does loxapine have "atypical" properties? Clinical evidence.
Glazer WM
J Clin Psychiatry; 1999; 60 Suppl 10():42-6. PubMed ID: 10340686
[TBL] [Abstract][Full Text] [Related]
10. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
11. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
12. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
13. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
14. Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences.
Aringhieri S; Carli M; Kolachalam S; Verdesca V; Cini E; Rossi M; McCormick PJ; Corsini GU; Maggio R; Scarselli M
Pharmacol Ther; 2018 Dec; 192():20-41. PubMed ID: 29953902
[TBL] [Abstract][Full Text] [Related]
15. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
16. Amisulpride: a review of its use in the management of schizophrenia.
Curran MP; Perry CM
Drugs; 2001; 61(14):2123-50. PubMed ID: 11735643
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
[TBL] [Abstract][Full Text] [Related]
19. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.
Margolese HC; Chouinard G; Kolivakis TT; Beauclair L; Miller R; Annable L
Can J Psychiatry; 2005 Oct; 50(11):703-14. PubMed ID: 16363464
[TBL] [Abstract][Full Text] [Related]
20. The importance of serotonin-dopamine interactions in the action of clozapine.
Meltzer HY
Br J Psychiatry Suppl; 1992 May; (17):22-9. PubMed ID: 1358125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
